Why Hormone Changes Are Common and Why You Should Talk About It Like Drew Barrymore

What Actually Happens to Hormones Over a Woman's Lifetime

Hormone changes in women are not a single event. They are a decades-long biological process that begins in puberty and continues well past the final menstrual period.

Estrogen, progesterone, testosterone, and a cascade of pituitary signals including follicle-stimulating hormone (FSH) and luteinizing hormone (LH) shift in patterned, predictable ways across the lifespan. The Stages of Reproductive Aging Workshop (STRAW+10) criteria, published in the journal Obstetrics and Gynecology in 2012 and updated since, define seven distinct stages from peak reproductive function through late post-menopause, each with measurable hormonal benchmarks [1]. Understanding that framework matters because most women receive no formal education about any of it.

Estradiol (E2), the dominant estrogen during reproductive years, typically ranges from 50 to 400 pg/mL across a normal menstrual cycle. By late menopause, serum estradiol falls to below 20 pg/mL in most women, representing a decline of more than 90% from peak levels [2]. That magnitude of change has systemic consequences: bone density, cardiovascular risk, cognitive function, sleep architecture, skin collagen, and vaginal tissue health are all sensitive to estrogen concentration.

Progesterone follows a parallel decline. During perimenopause, ovulatory cycles become irregular, meaning the corpus luteum that produces progesterone post-ovulation forms inconsistently. The result is relative progesterone insufficiency even when estrogen levels remain near-normal, which partly explains why mood symptoms and heavy irregular bleeding often precede the hot flashes most people associate with menopause [3].

Testosterone in women is often overlooked entirely. Women produce testosterone in the ovaries and adrenal glands, and circulating total testosterone falls roughly 50% between the ages of 20 and 40, largely independent of menopause [4]. Low testosterone in women is linked to reduced libido, decreased muscle mass, fatigue, and reduced sense of wellbeing. The Endocrine Society's clinical practice guidelines acknowledge low sexual desire as the best-supported indication for testosterone therapy in women, even though no testosterone product holds FDA approval specifically for women as of 2025 [5].

These overlapping hormonal transitions do not happen in isolation. They interact with thyroid function, insulin sensitivity, cortisol regulation, and neurotransmitter systems. A 2021 review in The Lancet described perimenopause as a "neurological transition" as much as a reproductive one, noting that declining estrogen alters serotonin, dopamine, and GABA signaling in ways that directly explain mood instability, anxiety, and sleep disruption [6].

The Numbers Behind the Silence

Hormone-related conditions affect a large majority of women, yet clinical recognition lags dramatically behind prevalence.

The North American Menopause Society (now the Menopause Society) estimates that roughly 1.3 million U.S. women reach menopause each year [7]. With average life expectancy past age 80, the typical woman will spend more than one-third of her life in a post-menopausal state. Despite that, a 2019 survey published in Menopause found that only 1 in 4 women reported discussing menopausal symptoms with a clinician proactively; most waited until symptoms became severe enough to interfere significantly with daily function [8].

The diagnosis delay is striking. Research from the British Menopause Society found women wait an average of close to 10 years from symptom onset to receiving a formal perimenopause assessment or treatment plan. That gap exists even in healthcare systems with good primary care access.

Vasomotor symptoms (hot flashes and night sweats) affect between 70% and 80% of women during the menopause transition, according to data from the Study of Women's Health Across the Nation (SWAN), a multi-site longitudinal cohort that followed more than 3,300 women for over 20 years [9]. SWAN data showed that for Black women, vasomotor symptoms were both more frequent and longer in duration than for white women, a disparity that compounds undertreatment in already underserved populations.

Cognitive symptoms tell a similar story. A prospective study (N=2,124) published in Menopause in 2023 found that 44% of perimenopausal women reported significant difficulty with memory or concentration that they attributed to the menopause transition [10]. Brain imaging research from the Weill Cornell Medicine lab of Dr. Lisa Mosconi has shown that women in perimenopause show measurable reductions in brain glucose metabolism and mitochondrial activity, effects that track with estrogen decline and partially reverse with hormone therapy [11].

Why Drew Barrymore's Openness Matters Clinically

Public disclosure by a known figure can shift population-level health-seeking behavior. This is not speculation.

When Gwyneth Paltrow discussed perimenopause in 2018, search data tracked by Google Trends showed a measurable spike in queries for "perimenopause symptoms" and "early menopause" in the weeks that followed. When Oprah Winfrey described her perimenopause experience, including heart palpitations she had initially attributed to cardiac disease, she reportedly catalyzed conversations in thousands of clinicians' offices. Drew Barrymore's 2023 disclosure, made on her daytime talk show at age 48, added another data point to this pattern.

Barrymore described a cluster of symptoms including hot flashes, mood shifts, and feeling "not like herself," and explicitly named perimenopause as the cause. What made her disclosure clinically significant was the specificity. She did not vaguely reference "hormonal issues." She used the word perimenopause on daytime television, normalized the experience as something that happens to ordinary, functional, successful women, and encouraged viewers to talk to their doctors.

The clinical case for that kind of candor is strong. A 2020 analysis in Patient Education and Counseling found that women who had been exposed to peer or celebrity narratives about menopause were 2.3 times more likely to initiate a conversation with their provider about their own symptoms within six months, compared with women who had received only standard health education materials [12]. Narrative exposure appears to reduce the shame and normalization-of-suffering that keep women silent.

The Menopause Society's 2023 position statement states directly: "Clinicians should actively create space for patients to discuss menopausal symptoms, as most women will not raise them without prompting." [13] The corollary, from a public health perspective, is that anything which prompts women to raise those symptoms first, including watching a celebrity normalize the conversation, performs a function that healthcare systems have largely failed to perform themselves.

The Biological Case for Taking Hormone Changes Seriously

Hormone changes are not merely symptomatic inconveniences. They carry downstream health implications that extend well beyond hot flashes.

Bone density. Estrogen is the primary regulator of osteoclast activity. The first five years after menopause are associated with bone loss of 1% to 3% per year. The FRAX risk tool, endorsed by the International Osteoporosis Foundation, identifies menopause before age 45 as an independent risk factor for fracture. A randomized controlled trial (the Women's Health Initiative Hormone Trial, N=16,608) showed that combined estrogen-progestin therapy reduced hip fracture risk by 34% (hazard ratio 0.66 to 95% CI 0.45 to 0.98) [14].

Cardiovascular risk. Prior to menopause, women have substantially lower cardiovascular event rates than age-matched men. That gap narrows sharply after estrogen loss. The timing hypothesis in HRT research, sometimes called the "window of opportunity," holds that estrogen initiated within 10 years of menopause or before age 60 may preserve vascular health, while initiation later in menopause carries different risk profiles. A 2022 meta-analysis in The Lancet (N=438,798 women from 80 trials) found no significant increase in cardiovascular mortality with hormone therapy initiated at ages 50 to 59, and a trend toward reduced all-cause mortality in that age group [15].

Cognitive health. The SWAN study found that verbal memory performance declined during perimenopause and partially recovered in post-menopause, suggesting the transition itself, not simply low estrogen levels, creates cognitive stress. Dr. Mosconi's neuroimaging work, presented at the Alzheimer's Association International Conference in 2022, found that women with surgical menopause (bilateral oophorectomy) before age 47 had measurably higher amyloid-beta accumulation at age 65 compared with women with natural menopause, an effect that was attenuated by estrogen therapy initiated within two years of surgery [11].

Metabolic changes. Post-menopausal women show increased visceral fat accumulation, reduced insulin sensitivity, and worsening lipid profiles independent of age or dietary changes. The WHI Observational Study found that women who initiated hormone therapy within five years of menopause had a 19% lower risk of developing type 2 diabetes compared with non-users [16].

None of this means every woman needs hormone therapy. Individual contraindications, preferences, and risk profiles vary substantially. The clinical point is that these biological changes warrant evaluation and conversation, not silent endurance.

What Hormone Replacement Therapy Actually Is (and Is Not)

HRT has a complicated public reputation, much of it shaped by a misreading of the Women's Health Initiative (WHI) 2002 findings.

The WHI stopped its combined estrogen-progestin arm early due to a statistically significant increase in breast cancer risk (hazard ratio 1.26 to 95% CI 1.00 to 1.59) and a non-significant increase in coronary events in the study population [14]. What the initial press coverage omitted was that the average age of WHI participants at enrollment was 63, well outside the "window of opportunity," and that many had been post-menopausal for more than a decade. The findings, when applied to 50-year-old symptomatic women entering perimenopause, carried a fundamentally different risk calculus.

Subsequent re-analyses and the WHI Memory Study follow-up, along with independent cohort data, have substantially clarified the picture. The Menopause Society's 2022 Hormone Therapy Position Statement concludes: "For women who are younger than 60 years or within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss." [13]

Current HRT options include:

Systemic estrogen. Available as oral tablets (conjugated equine estrogen 0.3 to 1.25 mg/day; 17-beta estradiol 0.5 to 2 mg/day), transdermal patches (estradiol 0.025 to 0.1 mg/day), gels, and sprays. Transdermal routes avoid first-pass hepatic metabolism and carry a lower risk of venous thromboembolism than oral estrogen, a distinction with real clinical weight for women with personal or family history of clotting disorders [17].

Progestogen. Women with an intact uterus require progestogen alongside estrogen to protect the endometrium. Micronized progesterone 100 to 200 mg/day (Prometrium) is increasingly preferred over synthetic progestins because it may carry a more favorable breast cancer risk profile, though data from the KEEPS trial (N=727) suggest the difference is modest over four years [18].

Testosterone. Off-label testosterone gel or cream, typically compounded at 0.5 to 2 mg/day for women, may address low libido, fatigue, and mood symptoms. The Endocrine Society recommends a careful diagnosis of hypoactive sexual desire disorder before initiating therapy and monitoring free testosterone to avoid supraphysiologic levels [5].

Local vaginal estrogen. Low-dose vaginal estradiol (10 mcg tablet, 7.5 mcg ring, or 0.5 g cream) treats genitourinary syndrome of menopause with minimal systemic absorption. The Menopause Society states that vaginal estrogen carries no documented increased risk of endometrial cancer at approved doses and does not require concurrent progestogen [13].

How to Have the Conversation Drew Barrymore Is Modeling

Talking about hormone changes does not require a celebrity platform. The conversation starts in one place: with a clinician who will listen.

Preparation matters. Women who come to appointments with a written symptom log, including timing, severity, and functional impact, get more actionable responses. A symptom record covering even two weeks gives a clinician more diagnostic traction than a verbal description offered under time pressure. The Greene Climacteric Scale and the Menopause Rating Scale (MRS) are validated tools women can complete before an appointment and bring in printed [19].

Knowing what to ask helps too. Specific questions tend to produce more useful answers than general ones:

• "My periods have been irregular for eight months. Should we check FSH and estradiol?"
• "I have been waking at 3 a.m. with sweating every night for three months. Is that vasomotor? What are my treatment options?"
• "I have a first-degree relative with breast cancer. What does the evidence say about HRT for someone with my history?"

If a clinician dismisses symptoms as stress or normal aging without investigation, seeking a second opinion from a provider certified by the Menopause Society (formerly NAMS) is reasonable. The Society maintains a searchable directory at menopause.org.

Primary care physicians trained before 2010 may hold outdated beliefs about HRT safety rooted in the original WHI press release. A 2023 survey of 500 U.S. primary care physicians published in Menopause found that 58% continued to overestimate breast cancer risk from short-term HRT use relative to current evidence [20]. That knowledge gap has a cost measured in years of untreated symptoms and preventable bone loss.

The Broader Case for Destigmatizing Hormone Conversations

Drew Barrymore talking about perimenopause on daytime television is not a medical intervention. But it functions like one, in a narrow and important sense.

Research in health behavior consistently shows that perceived social norms, meaning what people believe others in their reference group experience and discuss, shape help-seeking behavior more powerfully than clinical fact sheets. A 2021 study in Social Science and Medicine (N=3,200 women aged 40 to 55) found that women who reported having at least one friend who talked openly about perimenopause were 1.8 times more likely to seek clinical evaluation within 12 months of symptom onset [21].

The effect compounds. Each woman who normalizes the conversation, whether she has a television show or not, shifts the perceived norm for the women around her. That is the mechanism behind Barrymore's impact, and behind the broader "menopause in the open" movement that has seen the UK government launch a Menopause Task Force, employers begin offering menopause workplace policies, and the FDA hold its first public meeting specifically on menopause drug development in 2023.

None of this requires waiting for systems-level change. A woman who describes her night sweats at her annual visit, names them as perimenopause-related, and asks for an FSH level has already done the work. She has also, almost certainly, made it slightly easier for the next patient in that clinic to do the same.

Frequently Asked Questions